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About 5 decades have passed since the concept of moyamoya disease (MMD) was established in Japan.  
In that time,  many clinical MMD studies have been performed from several diﬀerent points of view,  
such as epidemiology,  pathophysiology,  surgical procedures,  and prognosis.  In addition,  rapid devel-
opments in MMD genetic analysis have occurred.  In light of all this activity,  clinicians must continu-
ally update their knowledge of MMD in order to improve the prognosis of MMD patients.  In this 
review article,  we summarize the clinical MMD studies and introduce cutting-edge ﬁndings regarding 
MMD.
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I n the 1960ʼs,  Japanese neurosurgeons ﬁrst described moyamoya disease (MMD),  in the 
English literature,  as a chronic occlusive cerebrovas-
cular disorder characterized by bilateral stenosis of 
the supraclinoid portion of the internal carotid arter-
ies with the formation of an abnormal vascular net-
work at the base of the brain [1,  2].  The term 
“moyamoya” is derived from a Japanese expression for 
something hazy,  like a puﬀ of cigarette smoke drifting 
in the air (Fig.  1) [2].  Because the incidence of MMD 
is higher in East Asian than other populations [3],  
MMD research on pathophysiology and the develop-
ment of surgical procedures have been conducted 
mainly in East Asian countries over the past 50 years.  
In this review article,  we introduce cutting-edge ﬁnd-
ings pertaining to the diagnosis criteria,  epidemiol-
ogy,  genetic factors,  symptomatology,  radiographic 
assessment,  pathophysiology,  treatment and prognosis 
of MMD.
Diagnostic Criteria
　 For a number of years,  we used the criteria pro-
posed by the Research Committee on Spontaneous 
Occlusion of the Circle of Willis in 1997 [4].  The 
criteria consisted of three principal factors as fol-
lows: (1) stenosis or occlusion at the terminal portion 
of the internal carotid artery (ICA) and/or at the 
proximal portion of the anterior and/or middle cere-
bral arteries; (2) abnormal vascular networks in the 
vicinity of the occlusive or stenotic lesions in the 
arterial phase; and (3) lesion bilaterality [4].  The 
diagnostic criteria were modiﬁed in 2015,  for the ﬁrst 
time in about 20 years.  The new diagnostic criteria 
followed the basic outlines of the criteria proposed in 
1997,  but with the key modiﬁcation that the “bilater-
ality” was omitted.  The newer criteria reﬂect the fact 
that it is necessary to perform cerebral angiography 
in patients with unilateral lesions or atherosclerotic 
lesions.
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Epidemiology
　 The prevalence of MMD has an ethnic bias with a 
high MMD incidence in countries in Eastern Asia,  
such as Japan and Korea [3].  In 2003,  a nationwide 
survey in Japan estimated that the total number of 
patients treated was 7,700 and that the prevalence and 
annual rate of newly diagnosed cases were 6.03/ 
100,000 and 0.54/100,000 population,  respectively 
[5].  The sex ratio (female-to-male) was 1.8,  and the 
peak of prevalence was in patients aged 10 to 14 years 
for females and in patients aged 20 to 24 years for 
males [5].  The prevalence of a family history of 
MMD was reported to be 12.1  [5].  In a total of 
11,402 healthy subjects who underwent a brain check-
up,  the percentage of subjects with asymptomatic 
MMD was reported to be 0.07 ,  and its prevalence 
was estimated in the Japanese population as 50.7/ 
100,000 people [6].  This prevalence is about 10 times 
as high as that reported in 2008 [5],  which indicates 
that there are potentially many patients with MMD in 
Japan.
Genetic Factors
　 Mineharu et al.  investigated 15 highly aggregated 
Japanese families (52 patients) to determine the 
inheritance pattern of familial MMD [7].  They 
reported that among a total of 135 oﬀspring of 
aﬀected people,  59 were patents with MMD or obliga-
tory carriers and concluded that the mode of familial 
MMD inheritance was autosomal dominant with incom-
plete penetrance [7].  Genetic analysis of MMD has 
developed remarkably and rapidly in recent years [8].  
Since the 1990s,  several genome-wide linkage analyses 
have been performed,  and the sole locus that has been 
conﬁrmed is located at 17q25 [8].  Among the most 
important genetic discoveries is that ring ﬁnger pro-
tein 213 (RNF213),  located in chromosome 17q25.3,  
is a susceptibility gene for MMD and the p.R4810K 
missense variant in the RNF213 increases its suscep-
tibility to MMD in East Asian populations [9].  It has 
been reported that the homozygous c.14576G＞A 
variant of RNF213 was correlated with some clinical 
manifestations of MMD,  such as younger age at onset,  
severity of ischemia (cerebral infarction),  and steno-
occlusive change of the posterior cerebral artery 
(PCA) [10].  It is possible that bilateral progression 
may be associated with the number of risk alleles in 
RNF213 in unilateral MMD patients [11].  Vascular 
endothelial growth factor (VEGF) and kinase insert 
domain containing receptor (KDR; one of the VEGF 
receptors) polymorphism have also been reported to 
inﬂuence the age of onset and formation of synangio-
sis-induced collateral vessels after bypass surgery 
[12].  These data indicate that the clinical manifesta-
tion of MMD depends on genetic factors and suggest a 
new approach to MMD pathophysiology.  In Caucasian 
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Fig. 1　 Typical angiographic ﬁndings in moyamoya disease.  Frontal (A) and lateral projection (B) angiography with injection of the right 
internal carotid artery shows severe narrowing of the terminal portion of the internal carotid artery with abundant collaterals resembling a 
“puﬀ-of-smoke” at the base of the brain.
MMD patients,  no association was found between 
MMD and the p.R4810K variant in RNF213 [13].  
Some studies conducted in central Europe MMD 
patients have demonstrated signiﬁcant associations 
with polymorphisms located in platelet-derived growth 
factor receptor beta and transforming growth factor 
beta 1 genes and with a polymorphism located in pro-
line/serine-rich coiled-coil 1 [14,  15].
Symptomatology
　 There are 2 main types of symptoms: ischemia and 
hemorrhage.  The distribution of these types diﬀers 
between children and adults.  Most children with MMD 
develop ischemic complications,  such as transient 
ischemic attack and cerebral infarction,  and approxi-
mately half of the adult patients have intracranial 
hemorrhage; the other half have ischemic complica-
tions [3].  In adult patients with MMD who are 40 
years of age or older,  the hemorrhagic type exceeds 
the ischemic type [16].  The most common symptom in 
ischemic MMD patients is motor disturbance,  and that 
in hemorrhagic MMD patients is consciousness distur-
bance [16].  In MMD,  symptoms in the same category
－ischemic or hemorrhagic－usually recur,  although 
it is rare for both types to occur in one patient.  
Hishikawa et al.  revealed that 9  of MMD patients 
experienced a stroke type involving both ischemia and 
hemorrhage,  and these 2 types of stroke showed both 
acute and chronic duration [17].  In this section,  we 
introduce 2 symptoms,  headache and involuntary 
movement,  which are speciﬁc to MMD.
　 Headache. About 20  of MMD patients exhib-
ited headaches as a symptom,  including a dispropor-
tionately large group of pediatric and younger MMD 
patients.  The headaches that accompany MMD are 
vascular in origin with migrainous features,  which can 
cause impairment of daily life activities in MMD 
patients.  A decrease in cerebral blood ﬂow (CBF) or 
cerebrovascular reserve and spreading cortical 
depression have been reported as possible mechanisms 
of the headaches in MMD patients,  and it has been 
demonstrated that revascularization can alleviate the 
headaches by improving perfusion pressure and cere-
bral circulation [18].
　 Involuntary movement. Various kinds of 
involuntary movement including chorea,  choreo-athe-
tosis,  dyskinesia,  dystonia,  limb-shaking,  and epilep-
sia-partialis continua,  are seen in MMD patients [19],  
with the representative movement being chorea.  
Females are more frequently aﬀected by chorea than 
males,  and pregnancy has been reported to be a risk 
factor for involuntary movement associated with MMD 
[19].  Underlying mechanisms such as ischemia of the 
basal ganglia-thalamocortical circuits,  increased sex 
hormones during pregnancy or due to the intake of oral 
contraceptive,  and hyperthyroidism have been pro-
posed [19].  Haloperidol is eﬀective for controlling 
the choreic movements and revascularization surgery 
has been suggested to be beneﬁcial because it normal-
izes the cerebral hypoperfusion [19].
Radiographic Assessment
　 Cerebral angiography. Cerebral angiography 
is the gold standard both for diagnosing MMD and 
assessing its progression.  The most popular and tra-
ditional classiﬁcation is Suzukiʼs grading system [2].  
According to Suzukiʼs grading system,  angiographic 
ﬁndings of MMD are classiﬁed into 6 categories 
(Table 1),  and this classiﬁcation is based on the tem-
poral serial changes in the degree of development of 
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Table 1　 Suzukiʼs grading system＊
Grade
Stage 1 Narrowing of carotid fork
Stage 2 Initiation of the moyamoya and dilatation of intracranial main arteries
Stage 3 Intensiﬁcation of the moyamoya and defects of the ACA and MCA
Stage 4 Minimization of the moyamoya and defects of the PCA
Stage 5 Reduction of the moyamoya and development of ECA collaterals
Stage 6 Disappearance of the moyamoya and circulation only via ECA and VA
＊Data are from Suzuki and Takaku [2].
ACA,  anterior cerebral artery; MCA,  middle cerebral artery; PCA,  posterior cerebral artery; ECA,  external carotid artery; VA,  vertebral 
artery.
moyamoya vessels [20].  That is,  Suzukiʼs grading 
system could indicate the compensatory nature of 
MMD,  where the external carotid artery (ECA) sys-
tem complements the steno-occlusive change in the ICA 
system [21].  Mugikura et al.  proposed a new grading 
system by modifying Suzukiʼs grading system and 
reclassiﬁed the angiographic ﬁndings on the basis of 
the severity of steno-occlusive lesions in the proximal 
part of the ACA/MCA and the degree of antegrade 
opaciﬁcation their branches (Table 2) [22].  This 
grading system is more useful for the precise staging 
of ICAs on a single angiography without the use of 
temporally serial angiographies as required by Suzukiʼs 
grading system [20].  Both Suzukiʼs grading system 
[2] and the system modiﬁed by Mugikura et al.  [22] 
are classiﬁcations for anterior circulation (ICA,  mid-
dle cerebral artery (MCA),  and anterior cerebral 
artery (ACA)) involvement,  and Mugikura et al.  also 
reported a classiﬁcation for posterior circulation 
(PCA) involvement [23].
　 Magnetic resonance imaging (MRI) and mag︲
netic resonance angiography (MRA). Because 
of the rapidly growing prevalence and recent advance-
ment of MRI in Japan,  MMD can only be deﬁnitively 
diagnosed using MRA with the MRA-based diagnostic 
criteria.  Houkin et al.  established the MRA scores 
based on the severity of ICA,  MCA,  ACA,  and PCA 
involvement and reported that they correlated well 
with Suzukiʼs grading system [24].  Ryoo et al.  dem-
onstrated that 3-Tesla MRI wall imaging was useful in 
distinguishing MMD from atherosclerosis [25].
　 Positron emission tomography (PET) and 
single photon emission computed tomography 
(SPECT). PET and SPECT are necessary to 
assess hemodynamics in MMD patients.  Some PET 
studies have reported that pediatric MMD patients 
have an increased regional oxygen extraction fraction 
(rOEF) relative to adult MMD patients [26] and the 
cerebral oxygen metabolism improves in pediatric and 
younger adult MMD patients without parenchymal 
lesions after bypass surgery [27].  In SPECT studies,  
it has been reported that MMD patients with low CBF 
at rest or with low vasodilatory capacity are prone to 
experience recurrent ischemic stroke [28] and basal/
acetazolamide brain perfusion SPECT performed at 
6 to 12 months after bypass surgery could predict 
further clinical outcomes of pediatric MMD patients 
[29].
Pathophysiology
　 MMD pathophysiology is closely related to both 
angioarchitecture and hemodynamics.  Suzukiʼs grading 
system represents the interaction between the ICA and 
ECA systems.  Hishikawa et al.  reported that steno-
occlusive lesions in ICAs ipsilateral to PCAs with 
lesions are signiﬁcantly advanced stages compared 
with lesions in ICAs ipsilateral to PCAs without 
lesions in MMD patients (Fig.  2) [20].  These data 
indicates that there is another important interaction in 
MMD between the anterior (ICA,  MCA,  and ACA) 
and posterior (PCA) circulation [23].  Miyamoto et al.  
ﬁrst reported that there was a correlation between 
posterior circulation involvement (steno-occlusive 
lesions of PCA) and the severity of ischemia in MMD 
[30].  In addition,  Yamada et al.  demonstrated that 
the degree of steno-occlusive lesions of PCA signiﬁ-
cantly decreased regional CBF in the aﬀected hemi-
sphere,  but Suzukiʼs grades had no impact on regional 
CBF [31].  This may be explained mainly by a 
decrease in the leptomeningeal collaterals from the 
PCA to the anterior circulation [23].  The clinical 
signiﬁcance of posterior circulation involvement in 
MMD is similar between pediatric and adult patients,  
with the only signiﬁcant diﬀerence being that less 
advanced ICA lesions could complicate the posterior 
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Table 2　 Modiﬁed grading system proposed by Mugikura et al.＊＊
ICA stage
I Mild to moderate stenosis around ICA bifurcation with absent or slightly developed moyamoya
II Severe stenosis around ICA bifurcation or occlusion of either ACA or MCA with developed moyamoya
III Occlusion of both ACA and MCA with developed moyamoya
IV Complete occlusion of both ACA and MCA with absence of or a small amount of moyamoya
＊＊Data are from Mugikura et al. [22].
ICA,  internal cerebral artery; ACA,  anterior cerebral artery; MCA,  middle cerebral artery.
circulation involvement in pediatric patients [20,  32,  
33,  34].  There may be 2 patterns of interaction 
between the anterior and posterior circulation: an 
early and a delayed form of interaction.  In patients 
with an early interaction,  posterior circulation 
involvement complicates less advanced anterior circu-
lation involvement and causes symptoms during child-
hood.  In patients with a delayed interaction,  posterior 
circulation involvement is correlated with advanced 
anterior circulation involvement and causes onset dur-
ing adulthood.  This hypothesis may explain the 
pathophysiology of the onset age biphasic pattern in 
MMD.
Treatment
　 Evidence for MMD treatment. Traditionally,  
surgical revascularization has been performed on 
ischemic MMD patients and its preventive eﬀect on 
recurrent ischemic stroke has been demonstrated [35,  
36].  According to the 2015 Japanese guidelines for 
the management of stroke,  surgical revascularization 
is recommended for the ischemic type of MMD.  The 
preventive eﬀect of surgical revascularization on 
rebleeding in hemorrhagic MMD patients has been 
debated for many years [37,  38].  The Japan Adult 
Moyamoya trial (JAM trial),  a multicenter randomized 
controlled trial,  reported in 2014,  provided informa-
tion on the therapeutic strategy for hemorrhagic type 
MMD [39].  There was a signiﬁcant diﬀerence between 
the surgical and nonsurgical groups,  suggesting that 
direct bypass had a preventive eﬀect against rebleed-
ing based on a Kaplan-Meier analysis [39].  Takahashi 
et al.  also showed that the MMD patients with poste-
rior hemorrhage were at higher risk of rebleeding and 
accrued greater beneﬁt from bypass surgery in a 
subgroup analysis of the JAM trial [40].  The JAM 
trial results suggested that surgical revascularization 
should be considered for hemorrhagic MMD patients 
in the 2015 Japanese guidelines for the management of 
stroke.
　 Surgical procedures. The surgical procedures 
for MMD include direct bypass,  indirect bypass and 
combined bypass.  The most popular procedure,  direct 
bypass,  involves is superﬁcial temporal artery to 
MCA (STA-MCA) anastomosis [41].  STA-ACA and 
occipital artery (OA)-PCA bypass procedures have 
been reported for the ACA and PCA territory [42,  
43].  Many indirect bypass procedures using various 
kinds of tissues as blood supply sources have been 
reported,  including encephalo-myo-synangiosis (EMS) 
[44],  encephalo-duro-arterio-synangiosis (EDAS) [45],  
the multiple burr hole surgery technique [46],  ribbon 
encephalo-duro-arterio-myo-synangiosis (EDAMS) [47],  
encephalo-duro-myo-arterio-pericranio-synangiosis 
(EDMAPS) [48],  and omentum transplantation [49].  
Mizoi et al.  showed that a patientʼs age appears to 
aﬀect the development of collateral formation from 
indirect bypass and that the direct bypass procedure 
should be the ﬁrst-line surgical treatment option for 
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Fig. 2　 Signiﬁcant correlation between the anterior and posterior circulation in moyamoya disease.  The lesions in the internal carotid 
artery (ICA) (A) and the ipsilateral posterior cerebral artery (PCA) without steno-occlusive lesion (B) are mild,  but the lesions in the ICA (C) 
and ipsilateral PCA with steno-occlusive lesions (D) are advanced.
adult MMD patients [50].
　 Perioperative management. There are some 
issues particular to perioperative management of MMD 
and overcoming these issues leads to good surgical 
outcomes.  Carbon dioxide is an important chemical 
mediator of cerebral vessels.  Both hypercapnia and 
hypocapnia can induce a reduction of regional CBF 
through the mechanism of vasoconstriction and steal 
phenomenon via vasodilation,  respectively.  Maintaining 
normocapnia is highly desirable for MMD periopera-
tive management in order to prevent ischemic compli-
cations,  especially in children [51].  A relatively high 
percentage of MMD patients experience transient 
neurological deﬁcits in response to various hemody-
namic changes in the postoperative course of direct 
bypass surgery during the acute phase.  Hypoperfusion 
is related to competing blood ﬂows from the collateral 
circulation,  new blood ﬂow from the STA,  and 
impaired cerebral autoregulation [52].  Fujimura et al.  
reported that about one-fourth of MMD patients who 
underwent direct bypass surgery experienced symp-
tomatic hyperperfusion and that adult-onset and hem-
orrhage-onset patients had a higher risk of symptom-
atic hyperperfusion [53].  A PET study revealed 
increases in the CBF and cerebral blood volume 
(CBV) and a decrease in OEF during hyperperfusion 
[54].  A preoperative increase in OEF [54] or CBV 
[55] has been reported to be a risk factor of hyper-
perfusion from the hemodynamic point of view.  A de 
novo ivy sign,  which refers to a linear high-signal 
intensity along the cortical sulci or brain surface on a 
ﬂuid-attenuated inversion recovery image,  could be 
useful in detecting postoperative hyperperfusion [56].  
Minocycline hydrochloride,  known as an inhibitor of 
matrix metalloprotease 9,  may,  with strict blood 
pressure control,  prevent symptomatic hyperperfu-
sion [57].
　 Surgical outcome. A review that included data 
from 1,448 surgically-treated pediatric MMD patients 
showed that the rates of perioperative stroke and 
reversible ischemic events were 4.4  and 6.1 ,  
respectively,  and 87  of the patients experienced 
complete disappearance of or reduction in symptom-
atic cerebral ischemia [35].  Kazumata et al.  reported 
that the prevalence of postoperative stroke related to 
direct/combined revascularization in adult MMD 
patients was signiﬁcantly higher than that in pediatric 
MMD patients [58].  Moreover,  they showed that in 
pediatric MMD patients,  perioperative stroke was 
signiﬁcantly more frequent in indirect bypass com-
pared with direct/combined bypass and that in adult 
MMD patients,  there were no signiﬁcant diﬀerences 
in postoperative stroke between direct/combined 
bypass and indirect bypass [58].  These data mean that 
the surgical procedures and the patientʼs age may have 
an inﬂuence on perioperative stroke.
Prognosis
　 The prognosis of young pediatric MMD patients,  
especially those younger than 4 years of age,  is poor 
because of the high prevalence of cerebral infarction 
[59].  Possible mechanisms underlying cerebral 
infarction in patients diagnosed before four years of 
age are the high frequency of steno-occlusive lesions 
of the PCA,  poor development of transdural collater-
als,  and a relatively insuﬃcient blood supply to the 
developing brain [59].  In a long-term follow-up study,  
pediatric patients with MMD showed a comparable 
rate of good social adaptation in adulthood [60],  but 
Funaki et al.  demonstrated that PCA involvement could 
be an underlying risk factor for unfavorable social 
outcome [61].  In adult MMD patients with ischemic 
symptoms,  PCA involvement at the initial onset was 
signiﬁcantly correlated with poor outcome,  and revas-
cularization of the MCA territory in patients with 
PCA involvement was eﬀective at preventing recur-
rent ischemic stroke [62].  The prognosis of hemor-
rhagic MMD patients who undergo conservative 
treatment is unsatisfactory and the most important 
factor related to the poor prognosis is rebleeding.  
Kobayashi et al.  demonstrated that the annual rebleed-
ing rate was 7.09 /person/year and after rebleeding 
the mortality rate rose 6.8  to 28.6  [63].  The JAM 
trial showed the preventive eﬀect of direct bypass 
surgery against rebleeding in hemorrhagic MMD 
patients,  but its mean follow-up period was only 4.32 
years [39].  Whether the preventive eﬀect of direct 
bypass surgery against rebleeding will continue for a 
longer period needs to be investigated.
Conclusions
　 We reviewed cutting-edge ﬁndings on the diagnosis,  
epidemiology,  genetic factors,  pathophysiology,  
treatment,  and prognosis of MMD.  This article is 
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intended to be useful to all neurosurgeons,  neurolo-
gists,  pediatricians,  anesthesiologists and neuroradi-
ologists who participate in the management of patients 
with MMD.
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